IQUIX

Clinical safety rating: caution

Comprehensive clinical and safety monograph for IQUIX (IQUIX).

How it works

DNA gyrase inhibitor; topoisomerase IV inhibitor; bactericidal against Gram-positive and Gram-negative bacteria by blocking DNA replication.

What the body does with it

Metabolism	Not extensively metabolized; limited systemic absorption after ophthalmic administration; if absorbed, hepatic metabolism via CYP450 is minimal.
Excretion	Primarily renal excretion of unchanged drug (approximately 70-80%). A smaller fraction is excreted as metabolites via the kidneys. Biliary/fecal elimination accounts for less than 10% of the dose.
Half-life	Terminal elimination half-life is approximately 4-6 hours. This short half-life supports twice-daily dosing in clinical practice (for ophthalmic suspension).
Protein binding	Approximately 50-60% bound to plasma proteins, primarily albumin.
Volume of Distribution	Volume of distribution is approximately 1.5-2.0 L/kg. This suggests extensive tissue distribution, though systemic exposure is low with ophthalmic use.
Bioavailability	Ophthalmic administration: systemic bioavailability is low (< 10%) due to absorption through conjunctiva and nasal mucosa; most of the dose is cleared via nasolacrimal drainage. For oral or intravenous routes, bioavailability is not clinically relevant as IQUIX is only approved for ophthalmic use.
Onset of Action	For ophthalmic administration, clinical effect (reduction of ocular inflammation) is typically observed within 1-2 hours after instillation. Peak effect occurs around 2-4 hours.
Duration of Action	Duration of action is approximately 8-12 hours, consistent with twice-daily dosing. Clinical studies show sustained anti-inflammatory effect throughout the dosing interval.

Classification & Brands

Dosing & administration

1-2 drops of 0.5% solution in affected eye(s) every 2 hours while awake for 2 days, then 1-2 drops every 4 hours while awake for up to 5 days total.

Dosage form	SOLUTION/DROPS
Renal impairment	No dose adjustment required for renal impairment; minimal systemic absorption.
Liver impairment	No dose adjustment required for hepatic impairment; minimal systemic absorption.
Pediatric use	Children ≥1 year: 1 drop of 0.5% solution in affected eye(s) every 2 hours while awake for 2 days, then 1 drop every 4 hours while awake for up to 5 days total.
Geriatric use	Same as adult dosing; no specific age-related adjustments, but monitor for ocular adverse effects.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for IQUIX (IQUIX).

Breastfeeding	Levofloxacin is excreted into human breast milk. The milk-to-plasma ratio is approximately 0.8. Due to potential for serious adverse reactions in nursing infants, including joint damage, consider discontinuing breastfeeding or the drug, taking into account the importance of the drug to the mother.
Teratogenic Risk	IQUIX (levofloxacin) is contraindicated in pregnancy due to the risk of arthropathy and other developmental toxicities observed in animal studies. First trimester: potential for organ malformations; second and third trimesters: increased risk of fetal cartilage damage and other adverse effects.

Warnings & precautions

■ FDA Black Box Warning

No FDA black box warning for ophthalmic use. Systemic fluoroquinolones carry a black box warning for tendinitis/tendon rupture, peripheral neuropathy, CNS effects (e.g., seizures, increased intracranial pressure), and exacerbation of myasthenia gravis.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to levofloxacin or any component of the formulation","History of tendinitis or tendon rupture with fluoroquinolone use (systemic)"]

Clinical Precautions

Precautions

["Do not inject subconjunctivally or introduce into anterior chamber","Prolonged use may result in overgrowth of non-susceptible organisms, including fungi","Hypersensitivity reactions, including anaphylaxis, may occur","Avoid wearing contact lenses during treatment"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

IQUIX

Clinical safety rating: caution

Comprehensive clinical and safety monograph for IQUIX (IQUIX).

How it works

DNA gyrase inhibitor; topoisomerase IV inhibitor; bactericidal against Gram-positive and Gram-negative bacteria by blocking DNA replication.

What the body does with it

Metabolism	Not extensively metabolized; limited systemic absorption after ophthalmic administration; if absorbed, hepatic metabolism via CYP450 is minimal.
Excretion	Primarily renal excretion of unchanged drug (approximately 70-80%). A smaller fraction is excreted as metabolites via the kidneys. Biliary/fecal elimination accounts for less than 10% of the dose.
Half-life	Terminal elimination half-life is approximately 4-6 hours. This short half-life supports twice-daily dosing in clinical practice (for ophthalmic suspension).
Protein binding	Approximately 50-60% bound to plasma proteins, primarily albumin.
Volume of Distribution	Volume of distribution is approximately 1.5-2.0 L/kg. This suggests extensive tissue distribution, though systemic exposure is low with ophthalmic use.
Bioavailability	Ophthalmic administration: systemic bioavailability is low (< 10%) due to absorption through conjunctiva and nasal mucosa; most of the dose is cleared via nasolacrimal drainage. For oral or intravenous routes, bioavailability is not clinically relevant as IQUIX is only approved for ophthalmic use.
Onset of Action	For ophthalmic administration, clinical effect (reduction of ocular inflammation) is typically observed within 1-2 hours after instillation. Peak effect occurs around 2-4 hours.
Duration of Action	Duration of action is approximately 8-12 hours, consistent with twice-daily dosing. Clinical studies show sustained anti-inflammatory effect throughout the dosing interval.

Classification & Brands

Dosing & administration

1-2 drops of 0.5% solution in affected eye(s) every 2 hours while awake for 2 days, then 1-2 drops every 4 hours while awake for up to 5 days total.

Dosage form	SOLUTION/DROPS
Renal impairment	No dose adjustment required for renal impairment; minimal systemic absorption.
Liver impairment	No dose adjustment required for hepatic impairment; minimal systemic absorption.
Pediatric use	Children ≥1 year: 1 drop of 0.5% solution in affected eye(s) every 2 hours while awake for 2 days, then 1 drop every 4 hours while awake for up to 5 days total.
Geriatric use	Same as adult dosing; no specific age-related adjustments, but monitor for ocular adverse effects.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for IQUIX (IQUIX).

Breastfeeding	Levofloxacin is excreted into human breast milk. The milk-to-plasma ratio is approximately 0.8. Due to potential for serious adverse reactions in nursing infants, including joint damage, consider discontinuing breastfeeding or the drug, taking into account the importance of the drug to the mother.
Teratogenic Risk	IQUIX (levofloxacin) is contraindicated in pregnancy due to the risk of arthropathy and other developmental toxicities observed in animal studies. First trimester: potential for organ malformations; second and third trimesters: increased risk of fetal cartilage damage and other adverse effects.

Warnings & precautions

■ FDA Black Box Warning

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to levofloxacin or any component of the formulation","History of tendinitis or tendon rupture with fluoroquinolone use (systemic)"]